Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2012

View Archived Issues

Quisinostat evaluated in phase II cutaneous T-cell lymphoma trial

Amicus and GSK report 6-month results from first phase III study of Fabry's disease monotherapy

Infectex begins phase IIb/III trial of SQ-109

RaQualia and Lilly to extend research term of ion channel collaboration

Cempra begins global phase III trial in CABP

Amgen's AMG-319 tested against lymphoma cells

Preclinical evidence of a novel dual-acting therapy for diabetes and obesity in nonhuman primates

PDE inhibitor evaluated in patients with BMD

Boosting ASO-mediated exon-skipping for the treatment of DMD

New serotonin 5-HT7 receptor ligands designed by Italian scientists

PharmaMar recommended to continue ADMYRE trial

Biogen Idec forms research consortium to develop new ALS treatments

Medivir reports topline results from phase III simeprevir trials

New tyrosine kinase inhibitors patented

The Medicines Company's pivotal SOLO-1 trial meets all endpoints

Sitavig approved in eight European countries for recurrent labial herpes

Bayer designs novel TTK protein kinase inhibitors

Swiss university presents new bombesin receptor ligands

Novel compounds for IBS patented

Merck Serono obtains additional indication approval for Erbitux in Japan

Tredaptive study fails to achieve primary endpoint

Development of a novel animal model for MLL-rearranged leukemia

Bayer files additional Japanese application for regorafenib in GIST

FDA approves Biotest's IVIG for primary humoral immunodeficiency

Pergamum's phase II trial of DPK-060 in outer ear infections meets endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...